Home » ARCA Announces Special Protocol Assessment With FDA for Bucindolol
ARCA Announces Special Protocol Assessment With FDA for Bucindolol
ARCA Biopharma Monday announced that it has reached agreement with the U.S. Food and Drug Administration (FDA) regarding a Special Protocol Assessment on the design of a clinical trial to assess the safety and efficacy of bucindolol in approximately 3,200 patients with chronic heart failure.
Forbes
Forbes
Upcoming Events
-
07May
-
14May
-
30May